Peripheral areterial occlusive diseases, stage 11 (intermittent cluadication). Raynaud's phenomenon. Sequelae of stroke, e.g. motor and sensory disorders. Senile dementia, e.g. memory impairment and loss of concentration. Dosage: Itabs. 2:3 times daily.
Capsule
مرتان يوميا
51 EGP
Peripheral areterial occlusive diseases, stage 11 (intermittent cluadication). Raynaud's phenomenon. Sequelae of stroke, e.g. motor and sensory disorders. Senile dementia, e.g. memory impairment and loss of concentration. Dosage: Itabs. 2:3 times daily.
Note: All the provided information about this drug does not substitute for consulting a doctor.